India’s medicines regulator (DCGI) says it wants to assess the quality of medicines in India, following complaints from the west.
He says this will cost about $40-50m Rupees, or less than $1 million dollars. This would be a welcome assessment, and it appears he wants to involve external experts such as Interpol. But as I have pointed out before, if the sampling method chosen by the Indian regulator is flawed then the results will be useless. Taking samples from NGOs to test could introduce biases, some known (depending on the aims of the NGO) some not. If the Indian regulator wants to improve western acceptance of Indian medicine quality, then he should involve some foreign experts who have actually overseen samplings to minimize bias.
If he doesn’t’ this will simply be a repeat of the 2008-10 CDSCO exercise, the results of which are unreliable.